From: Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study
Quartile | Range | Pfizer, N (%) | AstraZeneca, N (%) | P-value |
---|---|---|---|---|
Transportation | > 75 | 20 (100.0) | 13 (100.0) | – |
Handling and storage | 50–75 | 2 (10.0) | 1 (7.7) | 1.000 |
> 75 | 18 (90.0) | 12 (92.3) | ||
Vaccine preparation | < 50 | 1 (5.0) | 0 | 0.798 |
50–75 | 3 (15.0) | 3 (23.1) | ||
> 75 | 16 (80.0) | 10 (76.9) | ||
Pfizer preparation | 50–75 | 4 (20.0) | – | – |
> 75 | 16 (80.0) | – | ||
AstraZeneca preparation | > 75 | – | 13 (100.0) | – |
Pre-vaccination | < 50 | 2 (10.0) | 2 (15.4) | 0.413 |
50–75 | 0 (0.0) | 1 (7.7) | ||
> 75 | 18 (90.0) | 10 (76.9) | ||
Administration | > 75 | 20 (100.0) | 13 (100.0) | – |
Post-vaccination | 50–75 | 3 (15.0) | 3 (23.1) | 0.659 |
> 75 | 17 (85.0) | 10 (76.9) | ||
Total | > 75 | 20 (100.0) | 13 (100.0) | – |